IL17A and rheumatoid arthritis: A meta-analysis on efficacy of anti-IL-17 drugs on rheumatoid arthritis showed that secukinumab and ixekizumab were more effective compared to placebo; however, an increased risk of infection in the test group has also been reported [206].